CMXHF — CSL Limited

CSL Limited (CMXHF) is a biotechnology company listed on PINK. It is led by Paul F. McKenzie Ph.D., based in 655 Elizabeth Street, Melbourne, VIC, Australia, 3000, with about 32,698 employees. CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

Use this CMXHF page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CMXHF quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CMXHF SEC filings page. Lician reads the product cache first so this HTML stays unique to CSL Limited even when a live quote feed is slow.